Assessment of calcium events, pERK levels, NMDA receptor expression and extracellular zinc levels in <i>slc13a5</i> mutants. by Deepika Dogra (21072023)

“…<b>(M, M’, N, N’,</b> Q) Quantification of the fluorescence intensity (CTCF) ratios of Palm-ZP1:CellMask Orange in the plasma membrane. <i>5a</i>^{<i>−/−</i>}<i>;5b</i>^{<i>−/−</i>} larvae show a significant decrease in Palm-ZP1:CellMask Orange CTCF ratio in the plasma membrane compared to WTs. …”

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

“…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [³H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”

R117H-7T and R117H-5T function (+/-) ivacaftor: estimates from <i>in vitro</i> measurements of channel function and transcript analysis. by Jessica E. Char (476386)

“…Ivacaftor increases <i>P</i>_<i>O</i> 2–4 fold to give 15% (dashed line) to 30% WT function. …”

Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects:

Summary of measured parameters. by Aaron L. Sayler (19797446)

Subjects:

Raw data. by Aaron L. Sayler (19797446)

Subjects:

IFIT1 inhibits translation of incoming alphavirus-specific RNAs. by Josephine M. Reynaud (732822)

CRIF1 deletion stimulated the activation of the NF-κB signaling pathway in HUVECs. by Shuyu Piao (4731327)

Atrial and ventricular connexins and sodium channel genes expression levels in wt and Ts65Dn mice. by Matthieu Raveau (160575)

“…Ts65Dn show an overall decrease in connexin and sodium channel mRNA expression except for <i>Cx45</i> and <i>Cx30.2</i> in the atria. …”

Cytoplasmic deadenylase Ccr4 is required for translational repression of <i>LRG1</i> mRNA in the stationary phase by Duong Long Duy (3775429)

“…In the log-phase <i>ccr4Δ</i> mutant cells, <i>LRG1</i> poly(A) tail was longer and <i>LRG1</i> mRNA level was higher than those in the log-phase wild-type (WT) cells. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

The actin nucleator Cobl decreases significantly in the ipsilateral hemisphere and in the primary motorcortex (M1) during the first hours after ischemic stroke induced by MCAO. by Yuanyuan Ji (455424)

T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1 by Antonella Bresin (5819432)

“…In particular, the colony-forming efficiency (CFE) and the insulin-like growth factor 1 (IGF1)-induced proliferation are dramatically impaired, while apoptosis is increased, in KCs from <i>Tcl1-/-</i> mice when compared to WT. …”

SIRT1 mediated CRIF1 deficiency-induced NF-κB activation in HUVECs. by Shuyu Piao (4731327)

Fig 2 - by Masaru Sakai (1669627)